Mesoblast stock hit on gloomy data on stem cells for COVID-19

mesoblast ceo dr silvio itescu

I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial …

Mesoblast stock hit on gloomy data on stem cells for COVID-19 Read More »